secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2024-05-03T23:59:59+00:00
Accession:  0000950170-24-052481
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Q1 2024 core revenue $63.2M (+1% YoY), GAAP loss $0.45/share, reiterates FY guidance
--------------------------------------------------------------------------------

- Total revenue $64.5M; core revenue $63.2M (+1% YoY); FY2024 core revenue guidance reiterated at $280M.
- GAAP net loss $13.5M ($0.45 diluted loss per share); Non-GAAP loss $269K ($0.01 per share).
- Adjusted EBITDA loss $3.2M; cash from operations $7.3M in Q1.
- Cash, cash equivalents, and marketable securities $846.2M as of March 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000095017024052481/0000950170-24-052481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000095017024052481/flgt-20240503.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-052481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer